




- Adagrasib was recently approved for treatment of non-small cell lung cancer
- Targets the G12C point mutation to the Kirsten rat sarcoma oncogene (KRAS)
- KRAS oncogene homologue is associated with top three most fatal cancers (adenocarcinoma, non-small lung cancer, colorectal cancer)
- Lots of interest in KRAS inhibitors after discovery by Shokat lab!
  - · KRAS previously considered "undruggable"; however, an allosteric site was identified
- Process roue was needed to procure enough material for clinical trials

# 

### **Medicinal Chemistry Route**








### **Commercial Route**

**BnHN** 



Chen, C. Org. Process Res. Dev. 2023, 27, 530. https://doi.org/10.1021/acs.oprd.2c00386


88% over 3 steps

2. (S)-Mandelic acid





### **Commercial Route**



 $Chen, C. \textit{ Org. Process Res. Dev. } \textbf{2023}, 27, 530. \ \underline{https://doi.org/10.1021/acs.oprd.2c00386}$ 





### "Proof of Concept Route"

G

Improvements on previous routes:

Transition metal free
Protecting group free
Chromatography free
Five linear steps
45% overall yield
Late-stage installation of expensive
subunits


MeN


McLaughlin, M. Org. Lett. 2023, 25, 944. https://doi.org/10.1021/acs.orglett.2c04266











Improvements on previous routes:

Transition metal free

Protecting group free

Chromatography free

Five linear steps

45% overall yield

Late-stage installation of expensive

subunits

Moderate yield

Impurity removal

**D**, NaOt-Am, 82%

MeN

McLaughlin, M. Org. Lett. 2023, 25, 944. https://doi.org/10.1021/acs.orglett.2c04266





### Final Process Route


Cheng, C. Org. Process Res. Dev. 2024, ASAP. https://doi.org/10.1021/acs.oprd.4c00024





### Final Process Route

Impurity arising from base catalysed sulfide elimination, ring cleavage. yielding a nitrile, and ring closure via nucleophilic attack



KSM	API	process design (%)	process development (%)	yield increase (%)
7		77	94	17
6		60	70	10
12		34	74	40
	step 1, 8	74	94	20
	step 2, 9	94	94	0
	step 3, 11	82	83	1
	step 4, 13	85	93	8
	step 5, 1	80	89	9
	overall yield, <b>1</b>	39	61	21

Cheng, C. Org. Process Res. Dev. 2024, ASAP. https://doi.org/10.1021/acs.oprd.4c00024